CL2018002610A1 - Linfocitos t transfectados y receptores de linfocito t para el uso en la inmunoterapia contra el cáncer - Google Patents
Linfocitos t transfectados y receptores de linfocito t para el uso en la inmunoterapia contra el cáncerInfo
- Publication number
- CL2018002610A1 CL2018002610A1 CL2018002610A CL2018002610A CL2018002610A1 CL 2018002610 A1 CL2018002610 A1 CL 2018002610A1 CL 2018002610 A CL2018002610 A CL 2018002610A CL 2018002610 A CL2018002610 A CL 2018002610A CL 2018002610 A1 CL2018002610 A1 CL 2018002610A1
- Authority
- CL
- Chile
- Prior art keywords
- lymphocytes
- description refers
- peptides
- molecules
- methods
- Prior art date
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title 2
- 238000002619 cancer immunotherapy Methods 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 6
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 6
- 210000004698 lymphocyte Anatomy 0.000 abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 201000011510 cancer Diseases 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 108700018351 Major Histocompatibility Complex Proteins 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 abstract 2
- 150000001413 amino acids Chemical group 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 230000001024 immunotherapeutic effect Effects 0.000 abstract 1
- 238000009169 immunotherapy Methods 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464403—Receptors for growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Pathology (AREA)
- Hospice & Palliative Care (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
Abstract
LA PRESENTE DESCRIPCIÓN SE REFIERE A RECEPTORES DE LINFOCITO T (TCR) QUE SE UNEN A ANTÍGENOS ASOCIADOS A TUMOR (TAA) Y QUE PERMITEN RECONOCER ESPECÍFICAMENTE CÉLULAS CANCEROSAS, A LINFOCITOS T QUE EXPRESAN LOS MISMOS, A MÉTODOS PARA PRODUCIR LOS MISMOS, Y A MÉTODOS PARA TRATAR CÁNCERES CON LOS MISMOS. EN PARTICULAR, LA PRESENTE DESCRIPCIÓN SE REFIERE A VARIOS TCR Y A SUS VARIANTES QUE SE UNEN A MOLÉCULAS DE HLA DE CLASE I O II UNIDAS CON UN PÉPTIDO, COMO EL IGF2BP3-001 DOTADO DE LA SECUENCIA DE AMINOÁCIDOS KIQEILTQV (SEQ ID N.º 1). LA PRESENTE DESCRIPCIÓN SE REFIERE, ADEMÁS, A PÉPTIDOS, PROTEÍNAS, ÁCIDOS NUCLEICOS Y CÉLULAS DESTINADOS A LA UTILIZACIÓN EN MÉTODOS INMUNOTERAPÉUTICOS. EN PARTICULAR, LA PRESENTE DESCRIPCIÓN SE REFIERE A LA INMUNOTERAPIA CONTRA EL CÁNCER. LA PRESENTE DESCRIPCIÓN SE REFIERE, ADEMÁS, A EPÍTOPOS PEPTÍDICOS PARA LINFOCITOS T QUE ESTÁN ASOCIADOS A TUMORES, SOLOS O EN COMBINACIÓN CON OTROS PÉPTIDOS ASOCIADOS A TUMORES QUE, POR EJEMPLO, PUEDEN SERVIR COMO PRINCIPIOS ACTIVOS FARMACÉUTICOS EN COMPOSICIONES VACUNALES DESTINADAS A ESTIMULAR RESPUESTAS INMUNITARIAS ANTITUMORALES, O A ESTIMULAR EX VIVO LINFOCITOS T QUE DESPUÉS SERÁN TRANSFERIDOS A LOS PACIENTES. LOS PÉPTIDOS UNIDOS A MOLÉCULAS DEL COMPLEJO MAYOR DE HISTOCOMPATIBILIDAD (MHC), O LOS PÉPTIDOS COMO TALES, TAMBIÉN PUEDEN SER DIANAS DE ANTICUERPOS, DE RECEPTORES DE LINFOCITOS T SOLUBLES, Y DE OTRAS MOLÉCULAS DE UNIÓN.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662308970P | 2016-03-16 | 2016-03-16 | |
| GBGB1604494.3A GB201604494D0 (en) | 2016-03-16 | 2016-03-16 | Transfected T-Cells and T-Cell receptors for use in immunotherapy against cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2018002610A1 true CL2018002610A1 (es) | 2018-11-05 |
Family
ID=58314261
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2018002610A CL2018002610A1 (es) | 2016-03-16 | 2018-09-12 | Linfocitos t transfectados y receptores de linfocito t para el uso en la inmunoterapia contra el cáncer |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US10596242B2 (es) |
| EP (1) | EP4177264A1 (es) |
| CL (1) | CL2018002610A1 (es) |
| CO (1) | CO2018010808A2 (es) |
| DK (1) | DK3430037T3 (es) |
| ES (1) | ES2930681T3 (es) |
| HR (1) | HRP20221375T1 (es) |
| HU (1) | HUE060725T2 (es) |
| IL (1) | IL261787B2 (es) |
| LT (1) | LT3430037T (es) |
| MD (1) | MD3430037T2 (es) |
| MY (1) | MY193474A (es) |
| NZ (1) | NZ746387A (es) |
| PH (1) | PH12018501892A1 (es) |
| PL (1) | PL3430037T3 (es) |
| PT (1) | PT3430037T (es) |
| RS (1) | RS63727B1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4110901A1 (en) | 2020-02-24 | 2023-01-04 | immatics US, Inc. | Methods for expanding t cells for the treatment of cancer and related malignancies |
| TW202227616A (zh) | 2020-08-21 | 2022-07-16 | 美商英麥提克斯股份有限公司 | 分離ｃｄ８＋選擇ｔ細胞的方法 |
| DE102021100038A1 (de) | 2020-12-31 | 2022-06-30 | Immatics US, Inc. | Modifizierte cd8-polypeptide, zusammensetzungen und verfahren zu deren verwendung |
| CA3203118A1 (en) | 2020-12-31 | 2022-07-07 | Gagan BAJWA | Cd8 polypeptides, compositions, and methods of using thereof |
| US20230089392A1 (en) | 2021-09-20 | 2023-03-23 | Immatics US, Inc. | Monocyte depletion of t cells populations for t-cell therapy |
| WO2023081461A1 (en) | 2021-11-08 | 2023-05-11 | Immatics US, Inc. | Methods for generating cell spheroids |
| US20230348548A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
| WO2023212691A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | DOMINANT NEGATIVE TGFβ RECEPTOR POLYPEPTIDES, CD8 POLYPEPTIDES, CELLS, COMPOSITIONS, AND METHODS OF USING THEREOF |
| US20240066127A1 (en) | 2022-04-28 | 2024-02-29 | Immatics US, Inc. | Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof |
| WO2023215825A1 (en) | 2022-05-05 | 2023-11-09 | Immatics US, Inc. | Methods for improving t cell efficacy |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4440859A (en) | 1977-05-27 | 1984-04-03 | The Regents Of The University Of California | Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms |
| US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
| IN151589B (es) | 1978-12-22 | 1983-05-28 | Biogen Nv | |
| US4530901A (en) | 1980-01-08 | 1985-07-23 | Biogen N.V. | Recombinant DNA molecules and their use in producing human interferon-like polypeptides |
| US4678751A (en) | 1981-09-25 | 1987-07-07 | Genentech, Inc. | Hybrid human leukocyte interferons |
| US4766075A (en) | 1982-07-14 | 1988-08-23 | Genentech, Inc. | Human tissue plasminogen activator |
| US4582800A (en) | 1982-07-12 | 1986-04-15 | Hoffmann-La Roche Inc. | Novel vectors and method for controlling interferon expression |
| US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
| US4677063A (en) | 1985-05-02 | 1987-06-30 | Cetus Corporation | Human tumor necrosis factor |
| US4810648A (en) | 1986-01-08 | 1989-03-07 | Rhone Poulenc Agrochimie | Haloarylnitrile degrading gene, its use, and cells containing the gene |
| ES2659376T3 (es) | 2000-06-05 | 2018-03-15 | Altor Bioscience Corporation | Proteínas de fusión del receptor de linfocitos T y conjugados y procedimientos de uso de las mismas |
| CA2501870C (en) | 2002-10-09 | 2013-07-02 | Avidex Limited | Single chain recombinant t cell receptors |
| NZ570811A (en) | 2002-11-09 | 2009-11-27 | Immunocore Ltd | T cell receptor display |
| GB0304068D0 (en) | 2003-02-22 | 2003-03-26 | Avidex Ltd | Substances |
| US8003770B2 (en) | 2005-09-13 | 2011-08-23 | Mie University | T-cell receptor and nucleic acid encoding the receptor |
| US20090263574A1 (en) | 2008-04-21 | 2009-10-22 | Quinn Daniel E | Method of restoring an article |
| SI2172211T1 (sl) | 2008-10-01 | 2015-03-31 | Immatics Biotechnologies Gmbh | Sestavek s tumorjem povezanih peptidov in zadevnih cepiv proti raku za zdravljenje glioblastoma (GBM) in drugih vrst raka |
| GB0908613D0 (en) * | 2009-05-20 | 2009-06-24 | Immunocore Ltd | T Cell Reseptors |
| GB0911566D0 (en) | 2009-07-03 | 2009-08-12 | Immunocore Ltd | T cell receptors |
| TW201124530A (en) | 2009-12-01 | 2011-07-16 | Oncotherapy Science Inc | IMP-3 oligopeptides and vaccines including the same |
| CA3088393C (en) | 2010-09-20 | 2021-08-17 | Biontech Cell & Gene Therapies Gmbh | Antigen-specific t cell receptors and t cell epitopes |
| WO2013057586A1 (en) | 2011-10-19 | 2013-04-25 | Oslo Universitetssykehus Hf | Compositions and methods for producing soluble t - cell receptors |
| KR102165350B1 (ko) * | 2012-09-14 | 2020-10-14 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | Mhc ii형 제한된 mage-a3을 인식하는 t 세포 수용체 |
| EP2808392A1 (en) | 2013-05-28 | 2014-12-03 | Rheinische Friedrich-Wilhelms-Universität Bonn | Aptamers and use of the aptamers in the diagnosis and treatment of cancer |
| JP6628719B2 (ja) * | 2013-07-15 | 2020-01-15 | アメリカ合衆国 | 抗ヒトパピローマウイルス１６ ｅ６ ｔ細胞受容体 |
| GB201319446D0 (en) * | 2013-11-04 | 2013-12-18 | Immatics Biotechnologies Gmbh | Personalized immunotherapy against several neuronal and brain tumors |
| JP6770966B2 (ja) * | 2014-11-05 | 2020-10-21 | ジェネンテック， インコーポレイテッド | 細菌における２鎖タンパク質の生成方法 |
| GB201604494D0 (en) * | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Transfected T-Cells and T-Cell receptors for use in immunotherapy against cancers |
-
2017
- 2017-03-16 NZ NZ746387A patent/NZ746387A/en not_active IP Right Cessation
- 2017-03-16 EP EP22192967.2A patent/EP4177264A1/en not_active Withdrawn
- 2017-03-16 MD MDE20190102T patent/MD3430037T2/ro unknown
- 2017-03-16 IL IL261787A patent/IL261787B2/en unknown
- 2017-03-16 HU HUE17710963A patent/HUE060725T2/hu unknown
- 2017-03-16 LT LTEPPCT/EP2017/056289T patent/LT3430037T/lt unknown
- 2017-03-16 HR HRP20221375TT patent/HRP20221375T1/hr unknown
- 2017-03-16 ES ES17710963T patent/ES2930681T3/es active Active
- 2017-03-16 PT PT177109634T patent/PT3430037T/pt unknown
- 2017-03-16 RS RS20221044A patent/RS63727B1/sr unknown
- 2017-03-16 DK DK17710963.4T patent/DK3430037T3/da active
- 2017-03-16 MY MYPI2018703734A patent/MY193474A/en unknown
- 2017-03-16 PL PL17710963.4T patent/PL3430037T3/pl unknown
-
2018
- 2018-09-05 PH PH12018501892A patent/PH12018501892A1/en unknown
- 2018-09-12 CL CL2018002610A patent/CL2018002610A1/es unknown
- 2018-10-09 CO CONC2018/0010808A patent/CO2018010808A2/es unknown
-
2019
- 2019-05-16 US US16/413,939 patent/US10596242B2/en active Active
-
2020
- 2020-02-26 US US16/802,431 patent/US11730796B2/en active Active
-
2023
- 2023-06-28 US US18/343,502 patent/US20230321208A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| HUE060725T2 (hu) | 2023-04-28 |
| IL261787B (en) | 2022-11-01 |
| RS63727B1 (sr) | 2022-12-30 |
| US20230321208A1 (en) | 2023-10-12 |
| EP4177264A1 (en) | 2023-05-10 |
| US10596242B2 (en) | 2020-03-24 |
| HRP20221375T1 (hr) | 2023-01-06 |
| NZ746387A (en) | 2022-08-26 |
| DK3430037T3 (da) | 2022-11-21 |
| ES2930681T3 (es) | 2022-12-20 |
| MY193474A (en) | 2022-10-15 |
| US20190269769A1 (en) | 2019-09-05 |
| PH12018501892A1 (en) | 2019-07-08 |
| US20200188497A1 (en) | 2020-06-18 |
| PT3430037T (pt) | 2022-11-23 |
| IL261787A (en) | 2018-10-31 |
| LT3430037T (lt) | 2022-12-12 |
| MD3430037T2 (ro) | 2023-01-31 |
| CO2018010808A2 (es) | 2019-02-08 |
| US11730796B2 (en) | 2023-08-22 |
| PL3430037T3 (pl) | 2022-12-19 |
| IL261787B2 (en) | 2023-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2018002610A1 (es) | Linfocitos t transfectados y receptores de linfocito t para el uso en la inmunoterapia contra el cáncer | |
| CL2019003312A1 (es) | Nuevos péptidos (seq id no:122) y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer epitelial de ovario y otros tipos de cáncer.(divisional solicitud 201800124) | |
| CR20180490A (es) | Celulas t transfectados y receptores de linfocito t para el uso en la inmunoterapia contra el cancer | |
| CL2020000986A1 (es) | Nuevo péptido de seq id no: 33 para el uso en la inmunoterapia contra el cáncer de pulmón, incluido el cáncer de pulmón amicrocítico y otros tipos de cáncer (divisional de la solicitud no. 201701819) | |
| CL2023001346A1 (es) | Uso de péptidos en inmunoterapia contra cáncer de pulmón amicrocítico y otros. | |
| CL2018001531A1 (es) | Péptidos y combinación de péptidos para el uso en la inmunoterapia contra el cáncer de mama y otros tipos de cáncer | |
| AR103220A1 (es) | Péptidos y combinación de péptidos para el uso en la inmunoterapia contra el carcinoma hepatocelular (chc) y otros tipos de cáncer | |
| CL2019002093A1 (es) | Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de ovario y otros tipos de cáncer. | |
| CL2019002880A1 (es) | Péptidos y combinaciones de los mismos para el uso en la inmunoterapia contra diversos tipos de cáncer. | |
| CL2019002878A1 (es) | Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra la leucemia y otros tipos de cáncer. | |
| CL2019003422A1 (es) | Nuevos péptidos (seq id n°171), combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer. (divisional solicitud 201800545) | |
| CL2020000020A1 (es) | Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de pulmón, incluyendo el nsclc, el sclc y otros cánceres. | |
| CL2018002969A1 (es) | Inmunoterapia contra el melanoma y otros tipos de cáncer | |
| CL2019000460A1 (es) | Nuevos péptidos y estructuras de soporte para el uso en la inmunoterapia contra el carcinoma epidermoide de cabeza y cuello y otros tipos de cáncer. | |
| CL2021000177A1 (es) | Péptidos, combinaciones de péptidos, células y kits para el uso en la inmunoterapia contra el cáncer (divisional de la solicitud no. 201802360) | |
| CL2018001533A1 (es) | Nuevos péptidos y combinación de péptidos para el uso en la inmunoterapia contra varios tipos de cáncer | |
| CL2018002427A1 (es) | Péptidos y combinación de péptidos para el uso de la inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer. (divisional solicitud 201702346) | |
| CL2019003326A1 (es) | Nuevos epítopos celulares y nuevas combinaciones de epítopos celulares para el uso de la inmunoterapia del mieloma y de otros tipos de cáncer. (divisional solicitud 201703244) | |
| CO2017003772A2 (es) | Péptidos y combinación de péptidos para el uso en la inmunoterapia contra el carcinoma hepatocelular (chc) y otros tipos de cáncer | |
| CL2020002171A1 (es) | Nuevo péptido de seq id no: 12 y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra la leucemia mieloide aguda (lma) y otros tipos de cáncer. (divisional solicitud 201802827) | |
| CL2018002096A1 (es) | Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el linfoma no hodgkiniano (lnh) y otros tipos de cáncer | |
| AR107897A1 (es) | Linfocitos t transfectados y receptores de linfocito t para el uso en la inmunoterapia contra el cáncer |